Peak NRR of 173% in FY2021-Q3. Latest is 109% - that's -64pp from peak.
Doximity is above the Healthcare SaaS Public median by +0pp (cell median: 109%)
Doximity (DOCS) is a healthcare saas company at the public stage. As of its most recent disclosure (FY-2026), Doximity reported a Net Revenue Retention rate of 109% - a mid-pack result for B2B SaaS at this segment.
Doximity's NRR peaked at 173% in FY2021-Q3, 64pp above today's level. Over the past three years, the metric has contracted by 58pp.
Within its peer set (healthcare saas companies at public stage in the $25k-$100k acv band), Doximity's NRR is roughly in line with the cell median of 109%. Compare against the full peer cell aggregate for distribution and top performers.
Contract shape and forward-booked revenue.
Health scores, usage, and time-to-value when disclosed.
Logo flow per period (count-side complement to dollar-based NRR).
Revenue, ARR, and team-size denominators for the productivity ratios.
Support tiers: free · premium · enterprise
CS team segments: Strategic · SMB
CSM model: account-named
Education programs: Inaugural training summit
Customer Advisory Board: Yes
Top customer exec: Lisa Greenbaum - Chief Commercial Officer
CCO comp tied to retention: Yes - Clawback Policy recovery of erroneously awarded incentive-based compensation in the event of accounting restatement
Named CS initiatives across recent disclosures (newest first).
Introduction of HIPAA-compliant generative AI writing assistant to help physicians reclaim time spent on administrative tasks.
"Our HIPAA-compliant generative AI writing assistant helps physicians and other medical professionals reclaim the time they spend on administrative tasks"
New portal for pharma brand clients providing real-time insights, ROI tracking, and automated upsell recommendations.
"new Client Portal, which is now open to more than 40% of our pharma brand clients"
Product helping Nurse Practitioners find training programs and preceptorships to drive evergreen engagement.
"One of the new products that we're coming out with here is what we call NP Navigator"
Acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, to enhance platform technology.
"On July 29, 2025, the Company completed the acquisition of all outstanding shares of Pathway Medical Inc."
Acquired AI-based medical knowledge platform Pathway Medical Inc. for $26 million to enhance platform capabilities.
"In July 2025, the Company executed a definitive agreement to acquire all outstanding shares of Pathway Medical Inc."
Launching commercial AI Search offering to tap into pharma paid search budgets.
"we're ready to monetize against our clients' large paid search budgets. We launched... last week"
Deployment of AI workflow and scheduling tools to 140 health systems.
"As of today, 140 health systems have purchased our Clinical AI Suite"
Strategic shift to bundled modules to drive larger deal sizes and January launches.
"Fiscal 2025 revenue benefited from our strategic shift to more multi-module integrated offerings."
Challenges acknowledged by management. Useful peer signals - your team is probably not alone.
Lawsuits related to disclosure of user count and engagement rates.
"claims on behalf of a putative class of our investors... related to our disclosure of user count and engagement rates"
New workflow products require more time for content creation and MLR approval compared to legacy products.
"we anticipate we may see longer launch timelines due to the traction of our new workflow products."
Customers limiting budget dollars from crossing between calendar years, impacting fiscal Q4 revenue flow.
"they have set up more guardrails... wanting to do is limit budget dollars from crossing between calendar years."
Settlement of a class action lawsuit related to disclosure of user count and engagement rates.
"On December 24, 2025, the parties entered into a settlement... the Company has agreed to pay... $31 million"
Lawsuit alleging unauthorized access to an AI medical information platform.
"plaintiff alleges the defendants gained unauthorized access to its AI medical information platform."
Lawsuits related to disclosure of user count and engagement rates.
"The operative complaint brings securities law claims... related to our disclosure of user count and engagement rates."
Curated quotes about customer outcomes, retention, renewals.
"Our client portal... allows them to see our return on investment on a monthly basis... and make more course corrections."
"Our goal is always to help our customers get on channel as quickly as possible to maximize their ROI."
"With over 75% of Scribe users returning each and every week, we are thrilled to add another very sticky tool."
"Our existing customers continue to lead our growth. We finished the quarter with a net revenue retention rate of 118%."
"We finished the quarter with a net revenue retention rate of 118% on a trailing 12-month basis."
"The good news for us is we don't need to go get that many brand new clients to continue to grow with an NRR of 118%."
Side-by-side NRR, customer cohorts, commercial structure, and CS motion.
Doximity appears on 2 of our retention leaderboards.
Free to embed on your blog or board deck. Includes a small backlink to cust.co.
Or grab the data: JSON API →
| Period | NRR | GRR | Source type | Filing |
|---|---|---|---|---|
| FY-2026 | 109% | - | 10-K | source ↗ |
| FY2026-Q4 | 109% | - | earnings-call-transcript | source ↗ |
| FY2026-Q3 | 112% | - | 10-Q-mdna | source ↗ |
| FY2026-Q2 | 118% | - | 10-Q-mdna | source ↗ |
| FY2026-Q1 | 118% | - | 10-Q-mdna | source ↗ |
| FY-2025 | 119% | - | 10-K | source ↗ |
| FY2025-Q4 | 119% | - | earnings-call-transcript | source ↗ |
| FY2025-Q3 | 117% | - | 10-Q-mdna | source ↗ |
| FY2025-Q2 | 119% | - | 10-K | source ↗ |
| FY2025-Q1 | 114% | - | 10-Q-mdna | source ↗ |
| FY2024-Q2 | 114% | - | earnings-call-transcript | source ↗ |
| FY2024-Q1 | 117% | - | 10-K | source ↗ |
| FY2023-Q1 | 153% | - | 10-K | source ↗ |
| FY-2022 | 119% | - | 10-Q-mdna | source ↗ |
| FY2022-Q4 | 133% | - | 10-Q-mdna | source ↗ |
| FY2022-Q3 | 128% | - | 10-Q-mdna | source ↗ |
| FY2022-Q2 | 139% | - | 10-Q-mdna | source ↗ |
| FY2022-Q1 | 139% | - | 10-Q-mdna | source ↗ |
| FY-2021 | 117% | - | 10-Q-mdna | source ↗ |
| FY2021-Q3 | 173% | - | 10-Q-mdna | source ↗ |
| FY2021-Q2 | 167% | - | 10-Q-mdna | source ↗ |
Generate a live retention report against Doximity and your full peer cell. Ungated. Downloadable as PDF.